Skip to main content

Newest resources


Home-based administration of Sayana Press: review and assessment of needs in low-resource settings

A new presentation of the subcutaneous (SC) injectable contraceptive depot medroxyprogesterone acetate (DMPA) increases the possibilities for home and self-administration of this popular contraceptive method. Sayana® Press is DMPA-SC in the prefilled Uniject™ injection system and consists of one dose that provides 3 months of contraceptive protection. Studies indicate that lay caregiver and self-injection of various medications, including other injectable presentations of DMPA-SC, are acceptable and effective. Introduction of Sayana® Press in developing countries could extend injectable contraceptive delivery safely and effectively beyond the clinic and, eventually, into the home, allowing lay caregiver or self-administration. Research needs for low-resource settings include assessing the acceptability and feasibility of self-injection with Sayana® Press. Feasibility studies necessary for implementing a sustainable home-based delivery program include assessment of training, health systems, policies, infrastructure needs and programmatic considerations to optimize women’s ability to manage their self-injection schedule.

Institutional author(s): PATH
Individual author(s): Bonnie Keith, Siri Wood, Sara Tifft, Jane Hutchings
Publication date: 2014

Journal article Link to Journal Article

Sayana Press: can it be a “game changer” for reducing unmet need for family planning?

Sayana® Press (SP) is a 104-mg single dose of medroxyprogesterone acetate (MPA) in 0.65-mL volume, sterilely packaged in the Uniject device. Uniject is a pre-filled, non-reusable blister injection system consisting of a bubble reservoir with an integral, ultra-thin needle. In this issue of Contraception, a group of papers address the acceptability of Sayana® Press (also known as Depo subQ Provera 104™ in Uniject) and other research related to this new product. These papers also identify some of the challenges to SP reaching its full potential as a new contraceptive option in low-resource settings, especially in sub-Saharan Africa and South and Central Asia, where unmet need for family planning is the greatest. SP could be a “game changer,” in part, due to its potential for in-home or self-injection. In addition, given the safety and ease of subcutaneous injections with SP, some Ministries of Health may be more likely to enact policy change to permit community health workers (CHWs) and other community-level workers (e.g., drug shop keepers) to provide injectables in countries that currently only permit higher level providers to do so. At a reasonable price, this new product has the potential to expand contraceptive choice and use in underserved communities that otherwise might not have access to injectable contraceptives.

Institutional author(s): USAID
Individual author(s): Jeff Spieler
Publication date: March, 2014

Journal article Link to Journal Article

Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal

This study measured acceptability of DMPA-SC (Sayana® Press) among intramuscular DMPA (DMPA-IM) users. Current DMPA-IM users in Senegal and Uganda accepted DMPA-SC, and most preferred DMPA-SC over DMPA-IM. DMPA-SC can be safely introduced into family planning programs and administered by trained community health workers, with expectation of client uptake.

Contraception. 2014. May;89(5):361-7. Epub 2014 Feb 6. https://doi.org/10.1016/j.contraception.2014.01.022

 

 

Institutional author(s): FHI 360
Individual author(s): Holly M Burke, Monique P. Mueller, Brian Perry, Catherine Packer, Leonard Bufumbo, Daouda Mbengue, Ibrahima Mall, Bocar Mamadou Daff, Anthony K Mbonye
Publication date: February, 2014

Journal article Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal

Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate

Objectives: To evaluate feasibility, acceptability, continuation, and trough serum levels following self-administration of subcutaneous (sc) depot medroxyprogesterone acetate (DMPA).

Study design: Women presenting to a family planning clinic to initiate, restart or continue DMPA were offered study entry. Participants were randomized in a 2:1 ratio to self-or clinician administered sc DMPA 104 mg. Those randomized to self-administration were taught to self-inject and were supervised in performing the initial injection; they received printed instructions and a supply of contraceptive injections for home use. Participants randomized to clinician administration received usual care. Continued DMPA use was assessed by self-report and trough medroxyprogesterone acetate levels at 6 and 12 months.

Results: Two hundred fifty women were invited to participate, and 137 (55%) enrolled. Of these, 91 were allocated to self-administration, and 90/91 were able to correctly self-administer sc DMPA. Eighty-seven percent completed follow-up. DMPA use at 1 year was 71% for the self-administration group and 63% for the clinic group (p=0.47). Uninterrupted DMPA use was 47% and 48% for the self and clinic administration groups at 1 year (p=0.70), respectively. Serum analyses confirmed similar mean DMPA levels in both groups and therapeutic trough levels in all participants.

Conclusions: Sixty-three percent of women approached were interested in trying self-administration of DMPA, even in the context of a randomized trial, and nearly all eligible for enrollment were successful at doing so. Self-administration and clinic administration resulted in similar continuation rates and similar DMPA serum levels. Self-administration of sc DMPA is feasible and may be an attractive alternative for many women.

Implications: Self-administration of sc DMPA is a feasible and attractive option for many women. Benefits include increased control over contraceptive measures and less time spent on contracepting behaviors. Globally, self-administration has the potential to revolutionize contraceptive uptake by increasing the number of women with access to DMPA.

Institutional author(s): Baylor College of Medicine, Baystate Medical Center, Columbia University
Individual author(s): Anitra Beasley, Katharine O'Connell White, Carolyn Westhoff
Publication date: February, 2014

Journal article Link to Journal Article

Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal.

Sayana® Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject™, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP’s acceptability is unknown. We measured acceptability of SP among clinic-based providers (Senegal only) and community health workers. This open-label observational study was conducted in clinics in three districts in Senegal and community-based services in two districts in Uganda. Providers administered SP to clients seeking reinjection of DMPA IM. We conducted in-depth interviews with 86 providers (52 in Senegal, 34 in Uganda) to assess their experiences providing SP to clients.

Institutional author(s): FHI 360, Centre de Formation et de Recherche en Santé de la Reproduction (CEFOREP), Senegal Ministry of Health and Social Action, Uganda Ministry of Health
Individual author(s): Holly M Burke, Monique P. Mueller, Catherine Packer, Brian Perry, Leonard Bufumbo, Daouda Mbengue, Bocar Mamadou Daff, Anthony K Mbonye
Publication date: January, 2014

Journal article Link to Journal Article

Operational assessments of Sayana® Press provision in Senegal and Uganda

This study aimed to evaluate DMPA-SC (Sayana Press) management and administration in low-resource settings, focusing on how the delivery logistics, administration time, storage and waste-management requirements compare to the traditional intramuscular DMPA injectable (DMPA-IM).

Cover J, Blanton E, Ndiaye D, Walugembe F, Lamontagne DS. Operational assessments of Sayana® Press provision in Senegal and Uganda. Contraception. 2014 May;89(5):374-8. https://doi.org/10.1016/j.contraception.2014.01.005. Epub 2014 Jan 18. PMID: 24565737.

Institutional author(s): PATH
Individual author(s): Jane Cover, Elizabeth Blanton, Dieynaba Ndiaye, Fiona Walugembe, D Scott Lamontagne
Publication date: January, 2014

Journal article Operational assessments of Sayana® Press provision in Senegal and Uganda

Perceptions of home and self-injection of Sayana Press in Ethiopia: a qualitative study

Sayana Press is a registered trademark of Pfizer Inc. a new subcutaneous formulation and presentation of a popular injectable contraceptive, has the potential to expand non-clinic access to contraception, including home and self-injection (HSI). This study collected information from potential users and stakeholders on their perceptions and preferences, the feasibility of an HSI of Sayana Press program and key policy considerations. PATH conducted 62 interviews and 7 focus groups with family planning users, non-users, physicians, other health care providers and key informants in the Oromia region of Ethiopia. Participants watched a demonstration and tested the device on a model mid-interview. The study did not involve product use in humans. Women found the product easy to use, liked the simple design and valued the time and expense that could be saved through HSI of Sayana Press (HSI-SP). Of those with inhibitions about their ability to self-inject, most shifted their opinion favorably after demonstration. The majority of other stakeholders also supported HSI-SP and thought it could increase contraceptive use in Ethiopia, and they suggested that any successful program must include proper training and supervision, particularly regarding product storage and waste management. The data provide findings to stimulate further research and support future planning. They suggest that HSI-SP may meet the needs of many women if key requirements and challenges are met. It may also be necessary to revise policies and guidelines to integrate the approach with national family planning strategies. This study provides the first available data on perceptions, feasibility and requirements for HSI of Sayana Press in a low-resource setting. Findings provide insights that may guide future implementation strategies, strengthen non-clinic family planning access programs and stimulate continued research.

Institutional author(s): PATH
Individual author(s): Bonnie Keith, Siri Wood, Caitlin Chapman, Esthetu Alemu
Publication date: December, 2013

Journal article Link to Contraception journal

Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial

HIV-positive women need contraception to avoid unintended pregnancy and risk of vertical HIV transmission. We assessed acceptability of SP versus intramuscular DMPA (DMPA-IM) among HIV-positive women and their care providers in Rakai, Uganda. Women were randomized to DMPA-IM or SP at baseline, received the alternate product at 3 months, and chose their preferred method at 6 months. We determined preferences among new and experienced contraceptive injectable users who had tried both types of injection during the trial, and from providers before and after providing both types of injectables to clients.

Institutional author(s): USAID, Rakai Health Sciences Program, Makerere University
Individual author(s): Chelsea B. Polis, Gertrude F. Nakigozi, Hadijja Nakawooya, George Mondo, Frederick Makumbi, Ronald H. Gray
Publication date: November, 2013

Journal article Link to Journal Article

Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm

This study evaluated the pharmacokinetic profile of medroxyprogesterone acetate (MPA) following injection of Depo-SubQ Provera 104 (DMPA-SC) in the upper arm, a preferred injection site in developing countries. Injection of Depo-SubQ Provera 104™ in the upper arm provided sufficient MPA levels for contraceptive protection for 3 months (13 weeks). The uptake and metabolism of MPA when injected in the upper arm may be different from the abdomen and thigh.

 

Institutional author(s): FHI 360
Individual author(s): Vera Halpern, Stephanie L Combes, Laneta J Dorflinger, Debra H Weiner, David F Archer
Publication date: July, 2013

Journal article Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm

Acceptability of depo-subQ in Uniject

FHI 360’s PROGRESS project worked with ministries of health and local partners in Senegal and Uganda to conduct an acceptability study of the subcutaneous delivery of injectable contraceptives with the Uniject™ device (DMPA-SC, Sayana® Press). The study assessed acceptability among family planning clients and providers, including community health workers, and offered recommendations for the introduction of this method.

Institutional author(s): FHI 360
Publication date: June, 2013